BibTex RIS Kaynak Göster

-

Yıl 2015, Cilt: 6 Sayı: 2, 202 - 208, 13.07.2015
https://doi.org/10.5799/ahinjs.01.2015.02.0519

Öz

Adult stem cells have the potential to differentiate into multiple cell types and have usage about lots of regenerative medicine research fields. Especially bone marrow-derived mesenchymal stem cells have a wide range of case presentation. New discoveries about stem cell biology will progress new options about cellular therapy products and isolation of different stem cell types will increase hope for treatment of important illness such as Parkinson’s disease, diabetes, malign brain tumors. It is the aim of this review is to present an overview of the current status of stem cell researches in different clinical applications for experimental and therapeutic purposes in our country. J Clin Exp Invest 2015; 6 (2): 202-208

Kaynakça

  • Ural AU. Mesenchymal stem cell applications (adults). Turkiye Klinikleri J Hem Onc-Special Topics 2008;1:62-66.
  • Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: Phase I study results. J Neurosurg Spine 2005;3:173-181.
  • Park HC, Shim YS, Ha Y, et al. Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of Granulocyte-Macrophage colony stimulating factor. Tissue Engineering 2005;11:913-922.
  • Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282;1145-1147.
  • Findikli N, Kahraman S, Akcin O, et al. Establishment and characterization of new human embryonic stem cell lines. Reproductive BioMedicine Online 2005;10:617–627.
  • Gluckman E, Broxmeyer HE, Auerbach AD. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174-1178.
  • Yokuş O, Albayrak M. Early and late endocrinologic complications of the hematopoetic stem cell transplantation performed for hematologic malignancies. J Clin Exp Invest 2012;3:149-150.
  • Broxmeyer HE, Douglas GW, Hangoc G, et al. Human
  • umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 1989;86:3828-3832.
  • Tomblyn MB, Arora M, Baker KS, et al. Myeloablative
  • hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol 2009;27:3634–3641.
  • Locatelli F, Rocha V, Reed W, et al. Eurocord Transplant Group. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003;101:2137–2143.
  • Frassoni F, Gualandi F, Podestà M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008;9:831-839.
  • Berk Ö. High dose cemotherapy in solid tumours and otolog bone marrow transplantation treatment. Doğa Tr Tıp ve Ecz DC 1986;10:104-109.
  • Akan H, Beksaç M, Koç H. Autologous peripheral
  • blood stem cell transplantation: An alternative. Turkish Journal of Hematology and Oncology 1992;2:159-161.
  • Jocham D, Richter A, Hoffman L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594-599.
  • Doehn C, Richter A, Lehmacher W, Jocham D. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with MO renal-cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial. Folia Biol (Praha) 2003;49:69-73.
  • Hanna MG Jr, Hoover HC Jr, Vermorken JB, et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001;19:2576-2582.
  • Wallack MK, Sivanandham M, Ditaranto K, et al. Increase survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg 1997;226:198-206.
  • Vitolo U, Cortellazzo S, Liberati AM, et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplan-tation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol 1997;15:491-498.
  • Aydın H, Ovalı E, Kartı S, et al. Maturation, Antigen Loading and Optimization of Dendritic Cell. J Cell Therapy Reg Med 2010;1.
  • Schadendorf D, Ugurel S, Schuler-Thurner B, et al. DC study group of the DeCOG. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-570.
  • Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-ersus-host disease: a phase II study. Lancet 2008;371:1579-1586.
  • Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant, graft-versus-host disease. Transplantation 2006;81:1390-1397.
  • Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143–147.
  • Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763–776.
  • Siepe M, Heilmann C, Patrick S, et al. Stem cell research and cell transplantation for myocardial regeneration. Eur J Cardiothorac Surg 2005;28:318-324.
  • Özbaran M, Omay SB, Nalbantgil S, et al. Autologous peripheral stem cell transplantation in patients with congestive heart failure due to ischemic heart disease. Eur J Cardiothorac Surg 2004;25:342-350.
  • Smits AM, Patrick V, Rutger JH, et al. The role of stem
  • cells in cardiac regeneration. Stem Cell Review Series. J Cell Mol Med 2005;9:25-36.
  • Mitchell KE, Weiss ML, Mitchell BM. Matrix Cells from Wharton’s Jelly Form Neurons and Glia. Stem Cells 2003;21:50-60.
  • Olcay A, Nişancı Y, Sezer M, et al. Applications of Stem Cell Implantation in Cardiology. Arch Turk Soc Cardiol 2003;31:776-780.
  • Doral MN, Atay ÖA, Bilge O, et al. Current surgical treatment options for cartilage repair. Turkish Journal of Geriatrics 2011;Özel sayı 1: 95-100.
  • Haddo O, Mahroof S, Higgs D, et al. The use of chondrogide membrane in autologous chondrocyte implantation. Knee 2004;11:51-55.
  • Stosich MS, Mao JJ. Adipose tissue engineering from human adult stem cells: clinical implications in plastic and reconstructive surgery. Plast Reconstr Surg 2007;119(1):71-85.
  • Arvidson K, Abdallah BM, Applegate LA, et al. Bone regeneration and stem cells. J Cell Mol Med 2011;15:718-746.
  • Binnet MS, Başarır K, Emin N, et al. Recent applications of cellular therapy in orthopedic surgery. J Cell Therapy Reg Med 2010;1:17-22.
  • Parr AM, Kulbatski I, Tator CH. Transplantation of Adult Rat Spinal Cord Stem/Progenitor Cells for Spinal Cord Injury. J Neurotrauma 2007;24:835-845.
  • Feron F, Perry C, Cochrane J, et al. Autulogous olfactory ensheating cell transplantation in human spinal cord injury. Brain 2005;125:2951-2960.
  • Park HC, Shim YS, Ha Yoon, et al. Treatment of Complete Spinal Cord Injury Patients by Autologous Bone Marrow Cell Transplantation and Administration of Granulocyte-Macrophage Colony Stimulating Factor. Tissue Engineering 2005;11:913-922.
  • Karamehmetoğlu SS, Unal S, Karacan I, et al. Traumatic spinal cord injuries in İstanbul, Turkey, An epidemiological study. Parapligia 1995;33:469-471.
  • Deda H, İnci MC, Kürekçi AE, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 2009;11:18–25.
  • Kaptanoğlu E. Acute spinal cord injury: regeneration studies and stem cell applications in spinal cord injury. Türk Fiz Tıp Rehab Derg 2008;54:38-45,
  • Kaptanoğlu E, Attar A. Regeneration studies and stem cell applications in spinal cord injury. Türk Nöroşirürji Derneği Bülteni 2009;43-56.
  • Hussain MA, Theise ND. Stem-cell therapy for diabetes ellitus. Lancet 2004;364:203-205.
  • Hess D, Li L, Martin M, et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nature Biotechnology 2003;21:763-770.
  • Austin TW, Lagasse E. Hepatic regeneration from hematopoietic stem cells. Mech Dev 2003;120:131-135.
  • Ricardo SD, Deane JA. Adult stem cells in renal injury and repair. Nephrology 2005;10:276-282.
  • Stelzner M, Chen DC. To make a new intestinal mucosa. Rejuvenation Res 2006;9:20-25.
  • Kilinc S, Gurkan UA, Guvenc S, et al. Evaluation of Epithelial Chimerism After Bone Marrow Mesenchymal Stromal Cell Infusion in Intestinal Transplant Patients. Transplantation Proceedings 2014;46:2125-2132.
  • Ulmer FL, Winkel A, Kohorst P, et al. Stem cells-Prospects in dentistry. Schweiz Monatsschr Zahnmed 2010;120:860-872.
  • Tsukamoto Y, Fukutani S, Shin-Ike T, et al. Mineralized nodule formation by cultures of human dental pulp-derived fibroblasts. Arch Oral Biol 1992;37:1045-1055.
  • Buchaille R, Couble ML, Magloire H, et al. A substractive PCR-based cDNA library from human odontoblast cells: identification of novel genes expressed in tooth forming cells. Matrix Biol 2000;19:421-430.
  • Yokose S, Kadokura H, Tajima Y, et al. Establishment and characterization of a culture system for enzymatically released rat dental pulp cells. Calcif Tissue Int 2000;66:139-144.
  • Gronthos S, Brahim J, Li W, et al. Stem cell properties of human dental pulp stem cells. J Dent Res 2002;81:531-535.
  • Miura M, Gronthos S, Zhao M, et al. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci USA 2003;100:5807-5812.
  • Canoğlu E, Çehreli ZC. An Update of Regenerative Pulp Therapies. Hacettepe Univ Faculty of Dentistry Clinical Dentistry and Research 2008;32:21-27.
  • Mizuno H, Hyakusoku H. Mesengenic Potential and Future Clinical Perspective of Human Processed Lipoaspirate Cells. J Nippon Med Sch 2003;70:300-306.
  • Weiss RA, Weiss MA, Beasley KL, et al. Autologous cultured fibroblast injection for facial contour deformities: a prospective, placebo-controlled, Phase III clinical trial. Dermatol Surg 2007;33:263-268.
  • Sakrak T, Köse AA, Kivanç O, et al. The effects of combined application of autogenous fibroblast cell culture and full-tissue skin graft (FTSG) on wound healing and contraction in full-thickness tissue defects. Burns 2012;38:225-231.
  • Attar R, Attar E. Potential Use of Stem Cells in Infertilty Treatment. Türkiye Klinikleri J Urology-Special Topics 2008;1:102-106.
  • Sarkar K, Miller FW. Possible roles and determinants of microchimerism in autoimmune and other disorders. Autoimmun Rev 2004;3:454-463.
  • Lee ESM, Bou-Gharios G, Seppanen E, Khosrotehrani K, Fisk NM. Fetal stem cell microchimerism: natural-born healers or killers? Mol Hum Rep 2010;16:869-878.
  • Hermann BP, Sukhwani M, Winkler F, et al. Spermatogonial Stem Cell Transplantation into Rhesus Testes Regenerates Spermatogenesis Producing Functional Sperm. Cell Stem Cell 2012;11:715-726.
  • Reis MM, Tsai MC, Schlegel PN, et al. Xenogeneic transplantation of human spermatogonia. Zygote 2000;8:97-105.
  • Aydos K. New Research Area in Andrology: Spermatogonial Stem Cell Transplantation. Turkiye Klinikleri J Med Sci 2008;28:122-124.

Hücresel tedavi ürünlerinin klinik kullanım alanları

Yıl 2015, Cilt: 6 Sayı: 2, 202 - 208, 13.07.2015
https://doi.org/10.5799/ahinjs.01.2015.02.0519

Öz

Birden fazla hücre tipine farklılaşma özelliğine sahip yetişkin kök hücreleri pek çok rejeneratif tıp araştırma alanında kullanılmaktadır. Özellikle kemik iliği kaynaklı mezenkimal kök hücrelerin tedavide kullanımına ait geniş aralıklı bir olgu bildirimi vardır. Kök hücre biyolojisi hakkındaki yeni keşifler ve farklı kök hücre tiplerinin izolasyonu ile geliştirilen hücresel tedavi ürünlerinin kullanımı ile Parkinson, diyabet, kötü huylu beyin tümörleri gibi önemli hastalıklarda ilerleme kaydedilecektir. Bu derlemenin konusunu ülkemizdeki kök hücre ürünlerinin deneysel ve tedavi amaçlı olarak kullanıldığı çeşitli klinik araştırma alanları oluşturmaktadır.

Anahtar kelimeler: Kemik iliği, mezenkimal kök hücreler, kök hücre araştırmaları

Kaynakça

  • Ural AU. Mesenchymal stem cell applications (adults). Turkiye Klinikleri J Hem Onc-Special Topics 2008;1:62-66.
  • Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: Phase I study results. J Neurosurg Spine 2005;3:173-181.
  • Park HC, Shim YS, Ha Y, et al. Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of Granulocyte-Macrophage colony stimulating factor. Tissue Engineering 2005;11:913-922.
  • Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282;1145-1147.
  • Findikli N, Kahraman S, Akcin O, et al. Establishment and characterization of new human embryonic stem cell lines. Reproductive BioMedicine Online 2005;10:617–627.
  • Gluckman E, Broxmeyer HE, Auerbach AD. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174-1178.
  • Yokuş O, Albayrak M. Early and late endocrinologic complications of the hematopoetic stem cell transplantation performed for hematologic malignancies. J Clin Exp Invest 2012;3:149-150.
  • Broxmeyer HE, Douglas GW, Hangoc G, et al. Human
  • umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 1989;86:3828-3832.
  • Tomblyn MB, Arora M, Baker KS, et al. Myeloablative
  • hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol 2009;27:3634–3641.
  • Locatelli F, Rocha V, Reed W, et al. Eurocord Transplant Group. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003;101:2137–2143.
  • Frassoni F, Gualandi F, Podestà M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 2008;9:831-839.
  • Berk Ö. High dose cemotherapy in solid tumours and otolog bone marrow transplantation treatment. Doğa Tr Tıp ve Ecz DC 1986;10:104-109.
  • Akan H, Beksaç M, Koç H. Autologous peripheral
  • blood stem cell transplantation: An alternative. Turkish Journal of Hematology and Oncology 1992;2:159-161.
  • Jocham D, Richter A, Hoffman L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594-599.
  • Doehn C, Richter A, Lehmacher W, Jocham D. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with MO renal-cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial. Folia Biol (Praha) 2003;49:69-73.
  • Hanna MG Jr, Hoover HC Jr, Vermorken JB, et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001;19:2576-2582.
  • Wallack MK, Sivanandham M, Ditaranto K, et al. Increase survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg 1997;226:198-206.
  • Vitolo U, Cortellazzo S, Liberati AM, et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplan-tation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol 1997;15:491-498.
  • Aydın H, Ovalı E, Kartı S, et al. Maturation, Antigen Loading and Optimization of Dendritic Cell. J Cell Therapy Reg Med 2010;1.
  • Schadendorf D, Ugurel S, Schuler-Thurner B, et al. DC study group of the DeCOG. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006;17:563-570.
  • Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-ersus-host disease: a phase II study. Lancet 2008;371:1579-1586.
  • Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant, graft-versus-host disease. Transplantation 2006;81:1390-1397.
  • Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143–147.
  • Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763–776.
  • Siepe M, Heilmann C, Patrick S, et al. Stem cell research and cell transplantation for myocardial regeneration. Eur J Cardiothorac Surg 2005;28:318-324.
  • Özbaran M, Omay SB, Nalbantgil S, et al. Autologous peripheral stem cell transplantation in patients with congestive heart failure due to ischemic heart disease. Eur J Cardiothorac Surg 2004;25:342-350.
  • Smits AM, Patrick V, Rutger JH, et al. The role of stem
  • cells in cardiac regeneration. Stem Cell Review Series. J Cell Mol Med 2005;9:25-36.
  • Mitchell KE, Weiss ML, Mitchell BM. Matrix Cells from Wharton’s Jelly Form Neurons and Glia. Stem Cells 2003;21:50-60.
  • Olcay A, Nişancı Y, Sezer M, et al. Applications of Stem Cell Implantation in Cardiology. Arch Turk Soc Cardiol 2003;31:776-780.
  • Doral MN, Atay ÖA, Bilge O, et al. Current surgical treatment options for cartilage repair. Turkish Journal of Geriatrics 2011;Özel sayı 1: 95-100.
  • Haddo O, Mahroof S, Higgs D, et al. The use of chondrogide membrane in autologous chondrocyte implantation. Knee 2004;11:51-55.
  • Stosich MS, Mao JJ. Adipose tissue engineering from human adult stem cells: clinical implications in plastic and reconstructive surgery. Plast Reconstr Surg 2007;119(1):71-85.
  • Arvidson K, Abdallah BM, Applegate LA, et al. Bone regeneration and stem cells. J Cell Mol Med 2011;15:718-746.
  • Binnet MS, Başarır K, Emin N, et al. Recent applications of cellular therapy in orthopedic surgery. J Cell Therapy Reg Med 2010;1:17-22.
  • Parr AM, Kulbatski I, Tator CH. Transplantation of Adult Rat Spinal Cord Stem/Progenitor Cells for Spinal Cord Injury. J Neurotrauma 2007;24:835-845.
  • Feron F, Perry C, Cochrane J, et al. Autulogous olfactory ensheating cell transplantation in human spinal cord injury. Brain 2005;125:2951-2960.
  • Park HC, Shim YS, Ha Yoon, et al. Treatment of Complete Spinal Cord Injury Patients by Autologous Bone Marrow Cell Transplantation and Administration of Granulocyte-Macrophage Colony Stimulating Factor. Tissue Engineering 2005;11:913-922.
  • Karamehmetoğlu SS, Unal S, Karacan I, et al. Traumatic spinal cord injuries in İstanbul, Turkey, An epidemiological study. Parapligia 1995;33:469-471.
  • Deda H, İnci MC, Kürekçi AE, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 2009;11:18–25.
  • Kaptanoğlu E. Acute spinal cord injury: regeneration studies and stem cell applications in spinal cord injury. Türk Fiz Tıp Rehab Derg 2008;54:38-45,
  • Kaptanoğlu E, Attar A. Regeneration studies and stem cell applications in spinal cord injury. Türk Nöroşirürji Derneği Bülteni 2009;43-56.
  • Hussain MA, Theise ND. Stem-cell therapy for diabetes ellitus. Lancet 2004;364:203-205.
  • Hess D, Li L, Martin M, et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nature Biotechnology 2003;21:763-770.
  • Austin TW, Lagasse E. Hepatic regeneration from hematopoietic stem cells. Mech Dev 2003;120:131-135.
  • Ricardo SD, Deane JA. Adult stem cells in renal injury and repair. Nephrology 2005;10:276-282.
  • Stelzner M, Chen DC. To make a new intestinal mucosa. Rejuvenation Res 2006;9:20-25.
  • Kilinc S, Gurkan UA, Guvenc S, et al. Evaluation of Epithelial Chimerism After Bone Marrow Mesenchymal Stromal Cell Infusion in Intestinal Transplant Patients. Transplantation Proceedings 2014;46:2125-2132.
  • Ulmer FL, Winkel A, Kohorst P, et al. Stem cells-Prospects in dentistry. Schweiz Monatsschr Zahnmed 2010;120:860-872.
  • Tsukamoto Y, Fukutani S, Shin-Ike T, et al. Mineralized nodule formation by cultures of human dental pulp-derived fibroblasts. Arch Oral Biol 1992;37:1045-1055.
  • Buchaille R, Couble ML, Magloire H, et al. A substractive PCR-based cDNA library from human odontoblast cells: identification of novel genes expressed in tooth forming cells. Matrix Biol 2000;19:421-430.
  • Yokose S, Kadokura H, Tajima Y, et al. Establishment and characterization of a culture system for enzymatically released rat dental pulp cells. Calcif Tissue Int 2000;66:139-144.
  • Gronthos S, Brahim J, Li W, et al. Stem cell properties of human dental pulp stem cells. J Dent Res 2002;81:531-535.
  • Miura M, Gronthos S, Zhao M, et al. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci USA 2003;100:5807-5812.
  • Canoğlu E, Çehreli ZC. An Update of Regenerative Pulp Therapies. Hacettepe Univ Faculty of Dentistry Clinical Dentistry and Research 2008;32:21-27.
  • Mizuno H, Hyakusoku H. Mesengenic Potential and Future Clinical Perspective of Human Processed Lipoaspirate Cells. J Nippon Med Sch 2003;70:300-306.
  • Weiss RA, Weiss MA, Beasley KL, et al. Autologous cultured fibroblast injection for facial contour deformities: a prospective, placebo-controlled, Phase III clinical trial. Dermatol Surg 2007;33:263-268.
  • Sakrak T, Köse AA, Kivanç O, et al. The effects of combined application of autogenous fibroblast cell culture and full-tissue skin graft (FTSG) on wound healing and contraction in full-thickness tissue defects. Burns 2012;38:225-231.
  • Attar R, Attar E. Potential Use of Stem Cells in Infertilty Treatment. Türkiye Klinikleri J Urology-Special Topics 2008;1:102-106.
  • Sarkar K, Miller FW. Possible roles and determinants of microchimerism in autoimmune and other disorders. Autoimmun Rev 2004;3:454-463.
  • Lee ESM, Bou-Gharios G, Seppanen E, Khosrotehrani K, Fisk NM. Fetal stem cell microchimerism: natural-born healers or killers? Mol Hum Rep 2010;16:869-878.
  • Hermann BP, Sukhwani M, Winkler F, et al. Spermatogonial Stem Cell Transplantation into Rhesus Testes Regenerates Spermatogenesis Producing Functional Sperm. Cell Stem Cell 2012;11:715-726.
  • Reis MM, Tsai MC, Schlegel PN, et al. Xenogeneic transplantation of human spermatogonia. Zygote 2000;8:97-105.
  • Aydos K. New Research Area in Andrology: Spermatogonial Stem Cell Transplantation. Turkiye Klinikleri J Med Sci 2008;28:122-124.
Toplam 67 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Derleme
Yazarlar

Serpil Yanbakan Bu kişi benim

Yayımlanma Tarihi 13 Temmuz 2015
Yayımlandığı Sayı Yıl 2015 Cilt: 6 Sayı: 2

Kaynak Göster

APA Yanbakan, S. (2015). Hücresel tedavi ürünlerinin klinik kullanım alanları. Journal of Clinical and Experimental Investigations, 6(2), 202-208. https://doi.org/10.5799/ahinjs.01.2015.02.0519
AMA Yanbakan S. Hücresel tedavi ürünlerinin klinik kullanım alanları. J Clin Exp Invest. Temmuz 2015;6(2):202-208. doi:10.5799/ahinjs.01.2015.02.0519
Chicago Yanbakan, Serpil. “Hücresel Tedavi ürünlerinin Klinik kullanım Alanları”. Journal of Clinical and Experimental Investigations 6, sy. 2 (Temmuz 2015): 202-8. https://doi.org/10.5799/ahinjs.01.2015.02.0519.
EndNote Yanbakan S (01 Temmuz 2015) Hücresel tedavi ürünlerinin klinik kullanım alanları. Journal of Clinical and Experimental Investigations 6 2 202–208.
IEEE S. Yanbakan, “Hücresel tedavi ürünlerinin klinik kullanım alanları”, J Clin Exp Invest, c. 6, sy. 2, ss. 202–208, 2015, doi: 10.5799/ahinjs.01.2015.02.0519.
ISNAD Yanbakan, Serpil. “Hücresel Tedavi ürünlerinin Klinik kullanım Alanları”. Journal of Clinical and Experimental Investigations 6/2 (Temmuz 2015), 202-208. https://doi.org/10.5799/ahinjs.01.2015.02.0519.
JAMA Yanbakan S. Hücresel tedavi ürünlerinin klinik kullanım alanları. J Clin Exp Invest. 2015;6:202–208.
MLA Yanbakan, Serpil. “Hücresel Tedavi ürünlerinin Klinik kullanım Alanları”. Journal of Clinical and Experimental Investigations, c. 6, sy. 2, 2015, ss. 202-8, doi:10.5799/ahinjs.01.2015.02.0519.
Vancouver Yanbakan S. Hücresel tedavi ürünlerinin klinik kullanım alanları. J Clin Exp Invest. 2015;6(2):202-8.